GLP-1 drug manufacturers face nearly 100 lawsuits alleging the medications caused vision loss through a rare eye condition called NAION. While some research suggests a potential link, other studies found no association, and health authorities say evidence remains insufficient to establish causation. Novo Nordisk and Eli Lilly deny any significant relationship between their drugs and the condition.
Hundreds of Americans are suing GLP-1 drug makers after experiencing vision loss, including a Georgia nurse who lost sight in one eye while taking Wegovy. Patients report they were not adequately warned about the rare eye condition NAION, though drug companies dispute the link and claim labels contain appropriate warnings.